SCHEMBL867532

SCHEMBL867532

COCCc1c(O)c(=O)ccn1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.55
CYP2C9 P11712 2/20 0.55
KDM6A O15550 1/20 0.55
KDM4A O75164 1/20 0.55
CYP2C19 P33261 1/20 0.55
KDM5C P41229 1/20 0.55
KDM2B Q8NHM5 1/20 0.55
DOHH Q9BU89 1/20 0.55
KDM2A Q9Y2K7 1/20 0.55
MMP1 P03956 1/20 0.38
MMP7 P09237 1/20 0.38
MMP9 P14780 1/20 0.38
MMP8 P22894 1/20 0.38
MMP13 P45452 1/20 0.38
TP53 P04637 1/20 0.37
CYP2D6 P10635 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
COMT P21964 2/20 0.37
APP P05067 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4546216 0.82 KDM4E (0.58) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL8665858 0.81 KDM4E (0.45) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL6995058 0.78 KDM4E (0.62) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL869287 0.78 KDM4E (0.62) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL9700172 0.78 KDM4E (0.53) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL9700190 0.77 KDM4E (0.56) KDM4ECYP2C9KDM6AKDM4ACYP2C19
Hydrochloric Acid SCHEMBL6997040 0.77 KDM4E (0.60) KDM4ECYP2C9KDM6AKDM4ACYP2C19
Hydrochloric Acid SCHEMBL10404502 0.77 KDM4E (0.60) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL8615538 0.77 KDM4E (0.60) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL18117860 0.77 KDM4E (0.60) KDM4ECYP2C9KDM6AKDM4ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077852-A1 HYDROXYPYRIDINONES FOR THE LOCAL TREATMENT OF SKIN MICROCIRCULATORY DISORDERS CARLO GHISALBERTI (BR) 2012-03-29 US disclosed
EP-1567156-B1 HYDROXYPYRIDINONES FOR THE LOCAL TREATMENT OF SKIN MICROCIRCULATORY DISORDERS RELIVIA SRL (IT) 2009-08-26 EP disclosed
US-20060135448-A1 Hydroxypyridinones for the local treatment of skin microcirculatroy disorders RELIVIA S.R.L. (IT) 2006-06-22 US disclosed
EP-1567156-A2 HYDROXYPYRIDINONES FOR THE LOCAL TREATMENT OF SKIN MICROCIRCULATORY DISORDERS RELIVIA SRL (IT) 2005-08-31 EP disclosed
WO-2004045609-A2 HYDROXYPYRIDINONES FOR THE LOCAL TREATMENT OF SKIN MICROCIRCULATORY DISORDERS RELIVIA SRL (IT) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077852-A1 HYDROXYPYRIDINONES FOR THE LOCAL TREATMENT OF SKIN MICROCIRCULATORY DISORDERS HPGD, HPGDS, MVD KDM4E 1268/4885CYP2C9 2731/4885KDM6A 1930/4885
US-20060135448-A1 Hydroxypyridinones for the local treatment of skin microcirculatroy disorders HPGD, MVD, HPGDS KDM4E 1203/4885CYP2C9 3115/4885KDM6A 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.